Atossa Therapeutics Replaces $100M ATM with New $50M Offering, Securing Capital for Clinical Development

summarizeSummary

Atossa Therapeutics established a new $50 million At-The-Market (ATM) offering program, replacing its prior $100 million facility, to raise capital for clinical development and general corporate purposes.

check_boxKey Events

• New At-The-Market (ATM) Offering Initiated

  The company entered into an At-The-Market Offering Agreement with Rodman & Renshaw LLC to sell up to $50 million of common stock from time to time. This program allows for flexible capital raising for clinical development, working capital, and general corporate purposes.

• Prior ATM Program Terminated

  Atossa Therapeutics terminated its previous $100 million ATM agreement with Jefferies LLC, effective February 19, 2026. No shares were sold under the prior agreement, and no termination penalties were incurred.

• Potential Dilution and Capital Needs

  The new $50 million ATM program represents a substantial potential dilution for the company, given its current market capitalization. The proceeds are earmarked for critical operational needs, including advancing product candidates.

auto_awesomeAnalysis

Atossa Therapeutics has formally entered into a new At-The-Market (ATM) offering agreement for up to $50 million in common stock, concurrently terminating its previous $100 million ATM facility. This move, detailed in the 8-K filing, provides the company with continued access to capital for clinical development and general corporate purposes. While the new ATM represents a significant potential dilution relative to the company's current market capitalization, the reduction in the authorized offering amount from $100 million to $50 million could be viewed as a more disciplined approach to capital management. Investors should monitor the pace and pricing of any future share sales under this program, as substantial dilution could impact existing shareholder value. This 8-K provides the definitive legal agreements for the ATM program and its termination, which were also announced in concurrent 424B filings today.